CEB-01 is under clinical development by Cebiotex and currently in Phase I for Liposarcoma. According to GlobalData, Phase I drugs for Liposarcoma have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CEB-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CEB-01 overview
CEB-01 is under development for the treatment of leiomyosarcoma, liposarcoma, pleomorphic liposarcoma, nerve sheath tumor, solid tumors including neuroblastoma and Ewing sarcoma in pediatrics and surgical beds of soft tissue sarcoma in pediatrics and adults and pancreatic cancer in adults. It is developed based on nanofiber engineering technology that enables the production of non-woven nanofiber membranes, for the controlled release of therapeutic agents for the local treatment of unresectable tumors.
It was under development for the treatment of pediatric soft tissue sarcoma and solid tumor.
Cebiotex overview
Cebiotex is a biotechnology company. It offers biomedical solutions that help surgeons improve their operations and for the treatment of cancer patients. The company provides new medical product using technology in nanofiber engineering. Its pipeline products include CEB-01 which treats soft tissue sarcoma (STS), pancreatic cancer (PaC), ewing sarcoma (ES) and neuroblastoma (NB); CEB-02 treats glioblastoma (GBM). The company’s therapeutic areas include oncology in adults and pediatrics and hemostatic. Cebiotex is headquartered in Barcelona, Spain.
For a complete picture of CEB-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
